Virupos Ophthalmic Ointment
Acyclovir 3% Eye prep
3%
ZAS Corporation
| Pack size | 5 gm tube |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 600.00 AED |
Indications
Virupos Ophthalmic Ointment is used for:
Acute Herpetic Keratitis
Adult Dose
Acute Herpetic Keratitis
Indicated for acute herpetic keratitis (dendritic ulcers) in patients with herpes simplex virus (HSV-1 and HSV-2)
As 3% Eye oint:
Initial: Apply 1-cm ribbon to the affected eye 5 times/day until 3rd day of complete healing., followed by 7-day maintenance regimen
Maintenance: Apply 1-cm ribbon to affected eye 3 times/day for 7 days
Child Dose
Acute Herpetic Keratitis
<2 years: Safety and efficacy not established
>2 years
Indicated for acute herpetic keratitis (dendritic ulcers) in patients with herpes simplex virus (HSV-1 and HSV-2)
As 3% Eye oint:
Initial: Apply 1-cm ribbon to the affected eye 5 times/day until 3rd day of complete healing., followed by 7-day maintenance regimen
Maintenance: Apply 1-cm ribbon to affected eye 3 times/day for 7 days
Renal Dose
Administration
Ophthalmic Administration
Advise patients to wash hands well and pull down lower lid of the affected eye to form a pocket
Apply 1-cm (1/2 inch) ribbon of ointment in the pocket formed by the lower lid (the lower cul-de-sac)
After application, advise patient to close their eye for 1-2 minutes Wipe any excess ointment away
Contra Indications
Hypersensitivity.
Precautions
For ophthalmic use only
Patients should not wear contact lenses if they have signs or symptoms of herpetic keratitis or during the course of therapy
Pregnancy-Lactation
Pregnancy
A prospective epidemiologic registry of acyclovir use from 1984-1999 reported birth defects in women exposed to systemic acyclovir during the first trimester of pregnancy
Likewise, oral and SC administration of acyclovir to pregnant mice, rats, and rabbits during organogenesis did not produce teratogenicity at clinically relevant doses
Lactation
Acyclovir concentrations reported in breast milk following oral administration of acyclovir
There is no information regarding presence of acyclovir in human milk following ocular administration, effects on the breastfed infant, or effects on milk production
Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition
Interactions
No clinically significant interactions have been identified resulting from topical administration of other drugs.
Adverse Effects
Side effects of Acyclovir 3% Eye prep :
2-10%
Eye pain (stinging)
Punctuate keratitis
Follicular conjunctivitis
Frequency Not Defined
Blepharitis
Hypersensitivity reactions (eg, angioedema, urticaria)
Mechanism of Action
Activity against HSV types I and II and varicella-zoster virus is due to intracellular conversion of aciclovir to the monophosphate by viral thymidine kinase with subsequent conversion to the diphosphate and active triphosphate by cellular enzymes. This active form inhibits viral DNA synthesis and replication by interfering with viral DNA polymerase enzyme and being incorporated into viral DNA.
Note
Virupos 3% Ophthalmic Ointment manufactured by ZAS Corporation. Its generic name is Acyclovir 3% Eye prep. Virupos is availble in Bangladesh.
Farmaco BD drug index information on Virupos Ophthalmic Ointment is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.